Good afternoon, and welcome to the conference call of Fresenius Investor Relations, which is now starting. May I hand you over to Markus Georgi, Head of Investor Relations. Thank you, Andrea. Good morning, good afternoon, depending on your time zone. Thanks, everybody, for joining us today. It's my pleasure to welcome all of you to our third quarter 2023 earnings call. As always, with me on the call today, Michael and Sara. Before we start, I would like drawing your attention to the cautionary language that is included in our safe harbor statement on page 2 of today's presentation. And without any further ado, I hand it over to you, Michael. The floor is yours. Thank you, Markus. A warm welcome, everybody. This is Michael. Sara and I are going to review the business and financial highlights for Q3 fiscal 2023, emphasizing our achievements and deliverables on future Fresenius. Then obviously, we're gonna take your questions. It's been around a year plus since I became CEO, and there are two points I want everybody on the call to understand and hopefully appreciate. First, we're moving rapidly and delivering on the plans we set out. Our new management team is highly determined and committed, and more importantly, acting as a team. We're laser-focused on our key operating companies, Kabi and Helios. We've increased transparency in reporting and operations. We have simplified structures and straightened governance. Second, there is clear momentum behind the changes and improvements we've made. These are, and I really want to emphasize this, more than a one-time thing. Future Fresenius is aimed at permanently improving our operations and performance, as well as deepening our portfolio. Ultimately, it's about valuation. Let's now turn to how this all came out in the third quarter. Strong set of financials overall, group revenue growing nicely with 6% year-over-year in constant currency and earnings as an EBIT growing double-digit and delivering margin expansion. Results for Kabi and Helios, again, really very strong in the third quarter. Good top-line growth, growth, and even more impressive, clear upward movement in operating earnings and margins year-over-year. That's a trend paced by our cost-saving efforts that picked up speed over the years so far. Our work to simplify Fresenius also bore success. You saw already that we made our reporting more transparent, and the company structure is now much more straightforward. The vote in July to deconsolidate FMC was a major step forward. We are encouraged by management steps to build back FMC's value. You also saw the personnel changes we have been taking there, another crucial step forward. We have, of course, noted the strong valuation decline following Novo Nordisk's decision to terminate the FLOW study. We are excited about the potential benefits of GLP-1 agonists for patients and healthcare systems. We are looking forward to the release of the study. Clearly, let us all separate the signals from the noise. We are curious to see further study results, and even more importantly, real-world data on this drug and similar drug classes, how the drug helps different kind of patients, how they potentially slow down the progression of kidney disease and lower cardiovascular mortality, and if and how they can also help patients on dialysis to stay healthier and live longer. Obviously, our colleagues in our generics business are excited as well about any injectable drug reaching, at some point in time, blockbuster status, and then there is potential for us as a generic drug maker. Let me remind everybody that FMC numbers are now shown separately on the P&L, reflecting that it is an investment company for us, which also needs to deliver returns. The whole deconsolidation process, including the change of the legal form, is expected to be effective by December. So we are closing in on the final step. In less than one year, we decided, we acted, and delivered on a major and historical step for the company. The situation at our investment company, VAMED, has improved in Q3, as we have said. After challenges emerged this spring, we acted decisively and took consequences. Not finished yet, Q3 is back in the black, and actions are in place to improve even more looking forward, which they clearly also have to. We have spoken about our commitment to divest non-core assets. This will further sharpen our focus and streamline the group. It was never going to be an overnight process. This week, we announced the hospital exit in Peru, the first divestment transaction. We're making good progress on others, too, so watch this space. All in all, a great quarter, really delivering on all fronts. And again, it's about strengthening Fresenius to really carry out our core purpose: advancing patient care. Let's take a closer look at our operations for the first nine months, particularly at Kabi and Helios. And let me say, I really love this slide. Quarter by quarter, robust and consistent delivery.... At Kabi, strong top line growth, so the 3 + 1 strategy with focus on growth vectors is paying off. In the last 3 quarters, we have been delivering consistent execution on structural productivity on the back of strong revenue growth, reflecting our really strong position out there in the marketplace. Helios, our hospital operating segment, is just a solid and consistent performance engine. I am impressed by the reliability of the results. Mentioned VAMED already. We took tough actions and have the asset pointed in the right direction. Good revenue growth and back in profit, not finished yet. Taking this all together, we see delivery to plan and consistently quarter by quarter. Hence, we are going to improve the group EBIT outlook for 2023 to really reflect our confidence. Going a bit deeper into the operating companies, both of which delivered excellent numbers in Q3. At Kabi, both top line and EBIT level, Q3 was very strong. Kabi's revenue were up 7% year-over-year in organic terms, which is at the top end of the structural growth band. Revenues from Kabi's growth businesses, Nutrition, MedTech, and Biopharma, were up by a powerful 12% in Q3. The growth vectors really acted to accelerate revenue. Pharma is a stable top line grower, producing attractive earnings, so focus is really paying off. For EBIT, Kabi is again within its margin band at 14.3%. On an EBITDA basis, Kabi margins were even above 20%. Let me point out the very fact that all units at Kabi delivered margin expansion. Helios faced the usual, i.e., seasonal, softer summer months in admissions. Nevertheless, revenues were up 5% year-over-year at the top end of the revenue band. In terms of operating earnings, this was a solid quarter. Despite the lower volumes, we see both EBIT up meaningfully by 8% year-over-year and a 30 basis points margin expansion. Quirónsalud, our Spanish private hospital asset, is a prime part of this asset array with state-of-the-art medical technologies and digital solutions. So overall, Helios, very impressive in taking out costs in the face of still rising cost pressure. This is the self-help we've been talking about all along. Let's turn now to something we've been talking about for some time, and that is our debt profile. It has been pretty clear from the outset that we have too much leverage, which hits the P&L, especially when interest rates rise. This is probably the number one legacy topic based on trying to buy growth with cheap money. Hence, we instantly, at Q3 last year, changed our priorities and the business model. We deepened our focus on returns and self-help. It has been a priority of management, and I want to highlight the tools we're using to manage this downward. First is our focus on operating efficiency. You've already seen that Kabi and Helios are within the stringent margin bands we set out earlier this year. In addition, you can see our focus on spurring organic growth, and this is paying off with higher revenue growth from existing products and activities. Clearly, a big part of the story is the structural productivity, and here we have over-delivered. With about EUR 200 million in cost savings, excluding Fresenius Medical Care, we already realized our goal for 2023. Again, this is a permanent effect, and we are well ahead of expectation. This will continue moving forward. Divestments are advancing. We just announced the hospital exit in Peru. It is the first of a series of divestments that will tighten our focus, unwind complexity, and increase management focus on our core business. It also helps to save funds necessary in the future. The deal is expected to close in early 2024, more to follow in the coming months and quarters. A priority for management all pointed to improving value for shareholders and building our strength in the future. Let's take a look at some of the success stories of our operating companies in the third quarter. Let's start with Kabi, where we expanded our specialized healthcare product offerings with some important wins in Q3. We launched Tyenne, the first approved tocilizumab biosimilar in the European Union. This is a good example of the benefit we offer patients and healthcare professionals, while it also helps strengthen our growth profile, broadens our biopharma portfolio, and confirms our ability to develop state-of-the-art medicines. Being the first healthcare company to offer tocilizumab biosimilar in the EU, showcases Kabi's ambition to be a leading player in the biopharma space. The second example is the strategic partnership of mAbxience and Abbott. This collaboration with Abbott will enhance mAbxience's global presence, especially in emerging countries. This is clear evidence that we have an attractive pipeline of products and development capabilities that we can bring to the market also with renowned partners.... It is another good step in the important out-licensing biosimilar business. The enhanced global availability of more biosimilar products will undoubtedly benefit patients, health systems, and our partners in the regions. I'm very pleased that Fresenius Kabi has been named Supplier Partner of the Year by Vizient. It is great to see this recognition for our U.S. team, underlying their strong position in what is the largest market. Earning the trust and confidence of our customers is essential, and this award recognizes exactly this. Particularly, Kabi's response to drug shortages will remain a topic in this very important market. Congratulations, and thank you for your dedication and commitment to drive innovation and enhance quality of care and patient safety in the U.S. We aim to build on this strong foundation going forward. At Helios, we are fostering initiatives aimed at enhancing care delivery for our patients, and we also seek to constantly implement innovative initiatives to advance our operations. In Hamburg, Helios is piloting the use of AI to reduce energy consumption and CO₂ emissions. This involves the building of a digital twin in our ENDO-Klinik to simulate the likely needs and specifications of the building in advance. This opens a new chapter in the optimization of our hospital's buildings and operating efficiency. Not only will this help on the environmental front, but experts estimate energy savings potential of around 20%. Another proof point for the quality of our Spanish operations is the recognition of five Quirónsalud hospitals by Newsweek in its World's Best Specialized Hospitals 2024 ranking, which was based on a worldwide online survey of tens of thousands of medical professionals. In addition, the magazine has also published the Best Smart Hospitals ranking, including the Hospital Universitario Fundación Jiménez Díaz, among the 300 smartest hospitals in the world. Great achievement. Very proud of the whole team. All in all, another strong quarter of momentum on advancing patient care, a clear commitment to the Fresenius purpose. Thank you very much, Michael. A warm welcome also from my side. Michael has touched on our Q3 financial highlights already and given you some updates on product and service advances at both Kabi and Helios. It is an exciting time to be at Fresenius, and our employees deserve thanks for maintaining the momentum on our journey towards future Fresenius. The program is paying off. We have delivered clear progress on the financial metrics we outlined back in February. As you remember, the financial framework included managing revenue and EBIT towards strict bands, increasing capital return, managing leverage downward, and increasing cash conversion. As we said, this will take time, no quick solutions, and we have work to do, in particular on debt levels and cash generation. Looking at the results, you can see that operating performance accelerated consistently year-on-year. All numbers are excluding FMC, according to IFRS 5. Group revenue grew by 6% to EUR 5.5 billion, driven by a positive performance of our operating companies and VAMED. EBIT at EUR 519 million grew even stronger at 10%, driven by our operating companies. The challenges at VAMED are being addressed, and the operational turnaround is showing first encouraging signs with a positive EBIT contribution of EUR 10 million in Q3. Higher refinancing rates led to interest expenses up by more than 60% year-over-year. We expect to be around the middle of our EUR 400 million-EUR 440 million range for the full year. The tax rate before special items was 24.1% in Q3, due to some one-time items and phasing effects. For the first nine months, the tax rate stood at 25.2%, well within our expectation of 25%-26% for the full year. Operating cash flow was healthy at EUR 648 million, mainly due to the strong performance at Kabi. On debt, we reduced our leverage ratio by around 15 basis points from Q2 to Q3. At 4x, net debt EBITDA is, however, still too high. We have made progress and more will come. At the end of the year, we continue to target leverage below 4x. Not included is potential further deleveraging from divestments. Taking a closer look at the segments in Q3. Let's start with Kabi, where consistent revenue growth and success in driving down costs led to a strong performance. Kabi's revenues grew 7% organically to EUR 2 billion. That is at the top end of the structural growth bands. mAbxience is included in the organic growth for the first time and made a positive contribution. MedTech, Nutrition, and Biopharma, the three growth vectors, grew revenue by a combined 12% organically, an excellent top-line result. MedTech was up 8% organically, with broad-based improvements across all regions and product groups. Nutrition recorded organic growth of 9%, driven by positive developments in the U.S. and Latin America. China was softer due to indirect effects of the countrywide government anti-corruption campaign. Biopharma produced very strong organic growth of over 70%, driven by product sales and new product launches in Europe and the U.S., as well as licensing agreements. Pharma performed solidly with a growth rate of 1%, a robust development across many regions with a tough prior year-on-year comparison, in particular in the U.S. The EBIT margin for Kabi, at about 14%, was again very strong, with growth accelerating sequentially. Pharma contributed with strong constant currency growth of 9%, resulting in a margin of 21.3%. The growth sector showed a nice development, with 25% growth and a margin of 9.8%. Let me reiterate what Michael said: year-over-year, we saw margin expansion across all business units. Overall, an excellent achievement, driven by operational leverage from good revenue growth and ongoing progress on the cost and efficiency initiatives. Turning to Helios, remember that the summer had seasonally lower hospital admissions, in particular in Spain. Nevertheless, Helios performed very well, with strong 5% organic revenue growth year-over-year. That's been a consistent performance all year, at or above the upper end of its structural growth band. In Spain, organic revenue growth of 5% was driven by robust activity levels despite the holiday season. In Germany, growing patient volumes and favorable mix supported organic revenue growth at 4% for the quarter. Fertility continued its positive growth momentum, with 13% organic growth in Q3, supported by mix effects and price increases. At EUR 239 million, Helios' EBIT margin stood at 8.1%. This was, as expected for Q3, below the structural margin band of 9%-11%. Year-on-year, however, the margin improved by 30 basis points, demonstrating the relative strength of this quarter. We expect to be back in the structural margin band in Q4 and of course, for the full year. Overall, EBIT grew by a very strong 8%, supported by good activity levels, ongoing cost management, as well as government relief funds from energy-related cost increases in Germany. Let's now turn to VAMED. As we said, we made fixing the challenges there a priority for 2023. We conducted a strategy review of the business model and implemented management changes. Still, there is more to do, but we see clear progress and first signs of stabilization. Revenues increased by 13%, led by all three activities: high-end services, health facility operations, and health tech engineers. EBIT at EUR 10 million is back to positive, driven by high-end services and health facility operations. The project business will take a bit longer to restructure. And of course, the transformation resulted in some meaningful special items, of which a substantial portion was recorded in Q2. In Q3, we booked EUR 109 million of special items. Around one-third of this was restructuring costs aimed at profit improvement. The remainder related to discontinued business activities and the ongoing review of the order backlog. As outlined in Q2, more special items are to be expected as we continue to drive the transformation. Except for the restructuring costs, the special items are predominantly non-cash. For guidance-relevant purposes, they are excluded. Looking ahead, VAMED's management expects a solid operational Q4, with high-end services and health facility operations underpinning the performance. Based on the current status of the transformation program, VAMED reiterates its target to be within the structural margin band of 4%-6% by 2025 at the latest. Now, let's take a closer look at the IFRS 5 measurement effect for FMC in Q3. I will be brief, but happy to take questions. After the positive vote at FMC's EGM, IFRS 5 required an initial valuation of FMC at fair value. At the time of the vote in July, FMC's market capitalization exceeded the consolidated shareholders' equity, hence no impairment charge. However, IFRS 5 requires a continuous valuation at each balance sheet date. As of September thirtieth, FMC's market cap was EUR 12 billion and thus below our carried valuation of around EUR 14 billion. As a consequence, we were required to recognize a one-time non-cash special charge of EUR 2 billion, of which around EUR 600 million is attributable to shareholders of Fresenius SE. With the deconsolidation effective in December, we will move from IFRS 5 to at equity accounting. We expect further deconsolidation effects, depending on FMC's market capitalization at the time and some technical accounting adjustments.... But again, all recognized as special item without cash effect. On top of the good news on revenues and margins, another standout for me is our cost and efficiency program. Here we have delivered more savings than planned and at a faster rate. Again, our focus is on Fresenius, excluding Fresenius Medical Care. We recorded EUR 200 million of cost savings through the first nine months of 2023, which is the target we initially established for the full year. Kabi delivered the lion's share of these savings. Procurement measures and tighter SG&A control had the biggest impact. On a similar note, our one-time costs are tightly managed and well below our planned run rate. But the cost and efficiency programs are designed to permanently affect our performance. We have put our operations on a more efficient and streamlined basis to underline our commitment to build value in the long term. That means while we have achieved our full year plan already, we are of course, not going to stop or slow down on our overall target. We continue to execute and be focused on the cost savings we have outlined. Kudos to the management teams and the employees who achieved these productivity improvements. Taking a closer look at our cash flow development in Q3. Operating cash flow increased by 8% year-on-year to EUR 648 million, driven by the strong operating performance at Kabi and some working capital improvements. With several working capital and inventory initiatives, Kabi has a clear focus on cash generation. At Helios, cash performance was impacted by higher working capital, in particular at Helios Germany, as well as positive phasing effect at Helios Spain in the second half of last year. VAMED's cash flow improved year-over-year, mainly driven through phasing effects, positively impacting Q3. CapEx remains slightly below 5% in line with our full-year expectation. The Q3 performance took the group's last twelve months operating cash flow margin to 9%, with a last twelve months CapEx of 5%. With our capital allocation focus, we are spending CapEx in a very targeted way. We are also focusing strongly on improving our net working capital. A strong balance sheet is a key pillar of future Fresenius, and this includes reducing debt. We remain fully committed to the investment-grade rating as a 3-3.5 times leverage corridor. We know we must make this happen. It is a process, quarter-to-quarter, as we said. Fitch recognized our progress executing on future Fresenius and has improved the outlook for Fresenius credit rating to stable. For 2024, we have already completed our major refinancing activities with three debt issuances this year. All attracted excellent investor demand and further diversified our investor base and funding options. However, in the current interest rate environment, naturally, our priority is also to reduce debt and interest expense to regain more strategic flexibility and to increase earnings per share. Let me now conclude with our outlook for the remainder. All in all, a strong Q3 and first nine months of the year, we are executing on our future Fresenius agenda, and the performance has improved. The focus on Kabi and Helios is the right operational move. Obviously, we still have work ahead of us, be it reducing our debt level or ensuring VAMED continues to move into the right direction. Through the year, we have improved our guidance for Kabi as well as Fresenius top line, and now we can confirm that EBIT growth for the full year is expected to be broadly flat. On the top line, we continue to expect mid-single digit organic revenue growth for the full year. Now, let me hand it back to Michael. Many thanks, Sara. Before we get to questions, I want to quickly highlight the progress we've made at Fresenius in what we really believe is a relative short period of time. And yes, we still have work to do, and I'll also allude to this one. We've cleared away a lot of the complexity at Fresenius. FMC's deconsolidation gives us much more clearer and a simpler view of our operating performance, better transparency, and we retain optionality with our stake. Clearly, the greater operating focus on Kabi and Helios as the core of future Fresenius is paying off operationally and strategically. Costs are down faster than we planned and revenues are up, margins are improving fast and cash is being generated. And this is due to organic work throughout the Fresenius Group. And our divestment strategy is moving forward. Value is going to be realized in a thoughtful and disciplined manner. We have made good progress, and we remain comfortable with the timelines we laid out, and I look forward to sharing some updates in the coming months. Obviously, we will have bumps along the way. There is geopolitical uncertainty, inflation is still here, and healthcare continues to evolve quickly. Internally, we have legacy issues, and we're dealing with them, like VAMED and our debt level. Some things still need fixing. You saw how we're dealing with VAMED very quickly to transform the asset. We will deal with the debt levels in the same way. We have lots of ways to tackle it, and you will see steps to improve our strategic flexibility and to reduce our exposure. I continue to be proud of the Fresenius team worldwide. We want to keep this momentum going, and we aim to deliver on our change agenda. While improving company performance, we are also strengthening our corporate culture with improved governance and risk management. We had a great first nine months, which has allowed us to improve the operating earnings guidance for the current fiscal. This is the year which we identified as the year of structural progression. We are pleased with the foundation we have laid to make Fresenius even better and more valuable for 2024 and beyond. I am now one year and one month in my role as CEO of Fresenius. Seems like yesterday, and I'm now even more confident that Fresenius is a great place to work and thrive. We help save and improve the lives of patients with world-class products and services. What can be more relevant and important? In February this year, we embarked on our future Fresenius journey. We are still very early on, on that journey, but nevertheless, considerable progress has already been made. What makes it special is our purpose, that we work towards every day with all our associates, advancing patient care. Now, let's take questions. We are now starting the question and answer session. If you'd like to ask a question, please press star followed by one on your touchtone telephone. The operator will announce your name when it's your turn to ask a question. In case you wish to cancel your question, please press star followed by two. The first question comes from the line of Graham Doyle with UBS. Please go ahead. Good afternoon, guys. Thanks a lot for taking my questions. Just two for me. Firstly, just on costs, as we think about it, ex cost savings, so kind of stuff in the, in the COGS line, particularly for Kabi, as we look into next year. Are there any potential tailwinds around things like freight, raw materials, as we're seeing elsewhere for you guys, that could help for next year on the margin side? And then secondly, just would you be able to give us a little bit of an update with regards to Helios and government support, just in terms of what you're thinking is there at the moment, and I suppose, is there any sort of potential in the short term to maybe see a changing of capital allocation as a result of that? Thank you. Graham, hi, it's Michael. Let me start with the first question. I think it's too early to already make big assumption. Look, the world is very volatile. A lot of things are happening, and I would say at this point in time, it also makes limited sense to try to model one particular element because all the others are floating around. I think the reference point for all of you, but all of us, also, when Sara and myself are gonna start the budget process next week, is our financial framework. And the basis, the foundation we are laying for this current fiscal. So wherever we land in this current fiscal, and we improve the outlook today, will be the jump-off point. And then, as a reference, you have the margin bands for the operating companies. And yes, currently, we still see a pause on the interest rate lines and inflation, to some extent, has, you know, come to a halt in terms of further incremental inflation growth. That doesn't mean inflation isn't there. That doesn't mean it goes all the way through back through the whole value chain. And the average inflation of, I don't know what, 4 or 5% means something is at 8%, the other thing is at 3%. So I think it makes limited sense at this point in time. Reference point, take the margin, and I think we made it clear that at least the ambition should always be some continuous improvement. Now, the update on the government and particularly for Helios, particularly for Helios, Germany. Let me put all of this into context. Helios Germany, largest hospital chain in Germany, roughly 6 million patients a year, where we are saving the lives or improving the lives. Now, this is a regulatory business, and a part of being a regulated business is obviously a reimbursement model. So this is clear, this is like this in every region, so kind of like a fee-for-service reimbursement in Germany it's at least for the bulk of it, DRG driven. The intent, let me at least try to say what we believe is the intent of what the government did, is that in the future, all hospitals, obviously, also can expect an inflation compensation with a DRG inflator. What the government tried to do is to pull forward future compensations and to match it timing-wise with the costs which are incurred now, because the energy costs have been going up now incrementally high because of the terrible Ukraine war. And therefore, this is the intention to match future compensation elements pulling them forward to have a time match, because in essence, also in our business, we have seen real increase in energy. Now, there is obviously the fine print of that law, which has ramifications on dividends and bonus payments and everything. So the current status here is, the law has been rewritten a couple of times. Now it's in effect. We need to, first of all, fully understand. There's also an institution by the government where you can go to and clarify open topics because everything is not clear by the way it is written. We also will make up our mind whether it's constitutional or unconstitutional, and we will take everything into consideration and decide soon. The parameter for our decision-making will be what is in the best interest of our shareholders, and this is the way we're gonna go about. This is super. That's very clear. Maybe just a quick follow-up on biosimilars. Is there any color you can give us on where that strength is? Because it continues to form excellently as a division. The strength—I mean, the strength is in the launch. We saw, you know, at Tyenne launch, I think we disclosed it, beginning of the week, that we launched it in Europe. This is the, the Actemra biosimilar, also for rheumatoid arthritis and the like. By the way, just before the call, I double-checked, we got the first purchase order, even in Europe. So there, I think we're making good progress on, you know, developing the molecules and bringing them to market in time. The situation in the U.S., obviously, is a different one, with Idacio and Humira. I think there will be a lot of questions, maybe, following your questions, because there we see a highly competitive landscape, what we've been also anticipating. But the strength is in the pipeline. The strength is with partner, with mAbxience. You know, the deal with such a great company like Abbott is really great. It's a full array of molecules, primarily in the oncology space, which mAbxience will obviously develop and produce, and Abbott is the commercialization partner in countries other than the U.S. Also, mAbxience struck a deal with Amneal. They already had a deal with Amneal on Beva, and now there's another molecule coming. Great. Thanks a lot, guys. Appreciate it. The next question comes from the line of Veronika Dubajova with Citi. Please go ahead. Hi, Michael. Hi, Sara, and hi, Markus, and thank you for taking my questions. I have three, please. The first one is, I just want to follow up on a comment that Sara had made in her prepared remarks. Sara, you said that your priority is to reduce debt and to do it rapidly. I just would love to understand what other options beyond obviously, improving operationally the performance of the business you're considering to do that. And how seriously are you, given the current interest rate environment, considering monetizing other assets within the business to reduce the debt burden and increasingly the growing interest burden? So that's my number one. Number two, and I apologize, both of these questions are quite difficult to answer, but I think they need to be asked. My second question is on FMC and the implication of GLP-1. I think, Michael, you had said you're looking at the flow data to assess the impact. Can you give us some insights into what you need to see or what you will be looking out for when that flow data comes out? And under what scenarios might you reconsider the value creation pathway for FMC that, that you have in your mind? And then, then my sort of third question is just to follow on to Graham's around the government support and your thoughts on the dividend. Just how important is it in your mind to pay dividend versus drive leverage further down? If you could comment on that. That kinda ties to the first question anyhow. Maybe you can answer it together. I'll stop and let you guys comment on all of those. Thank you. I start? Happy to start on the debt question and the, I would say, pecking order on how we aim to reduce debt. And I think we do have a very clear pecking order, and we even outlined it back in February. It is, as you said, focusing on increasing operational performance. It is also on focusing on profitability and cost savings. And I think our cost-saving program is really aimed at making ourselves more profitable and having more falling through. And then thirdly, is capital allocation, and I think we have been very verbal about that, that we are on a very stringent capital allocation plan and that we are spending CapEx according to our strategy and also to a very deliberate set of KPIs. And so that set of capital allocation and being rigid there is also helping in reducing the debt. Last, but clearly not least, is the focus on cash. With that, I really mean, cash conversion and the focus on inventory, on working capital more broadly, and on cash collection. I think that's the clear, I would say, pecking order on how we intend to reduce debt. You mentioned asset monetization. Clearly, proceeds realized from asset monetizations will be used to reduce debt. At the same time, for me, that's more of a strategic question in terms of which assets are we not the best owner of? Which assets may consume too much capital in the future, and we don't want to put that capital there. Also, what we outlined in February to say, we sharpen the focus and we reduce complexity. So those would be my pecking order for divestments, and falling out of that, the proceeds will be used for deleveraging, but it's not deleveraging driven. Yes, yes, I can only echo this one. It is important to understand when we embarked on future Fresenius, we said, "What is the core? And whatever is non-core, we need to find a solution." And if and when it can help also as a happy by-product on the other thing, that is great. Because don't forget, the whole debt reduction has two elements. We got the net debt to EBITDA. Obviously, when you have an asset, which is great and finds a different home, the EBITDA is also gone, right? But might be reflected in proceeds and the like, and then we know how to use it. On the other hand, it is also about reducing the interest rate line in our P&L. And therefore, Veronica, you were quite right by saying the first question is tied to the third question. And we have not made a decision yet, but I shared with you as to how we are approaching this one, because there's a lot of, you know, judgment and diligence to be made. This is a law, and we have to deal with it. Also, the stance on being constitutional or unconstitutional. But there's a clear parameter for us, which is what is in the best interest of the shareholder. Whatever drives shareholder value, sustainable shareholder value, and we're targeting EPS growth, this may guide us. And I've read analyst reports and even newspaper articles who gave us unasked advice, but sometimes, you know, at least parameters look the same. So that answers maybe your third question, how are we gonna deal with this with a dividend? And again, it is something which is a pull forward by the government in order to match the costs incurred, and we didn't have an opt-out clause, by the way, from the very beginning. And therefore, yes, we also run hospitals, so we also received it, and now we're gonna decide how we go about it. On the GLP-1, I did not wanna be cynical, but at the end of the day, what I'm trying to say is there are so many questions still out there, so that we then, after those things are there, can really differentiate between the signal and the noise. It's great, the potential it has for patients and healthcare system, but, you know, every patient is different. What does it do to the progression of kidney disease, when we see the real-world data and the full data? Does it increase or decrease the life expectancy? Does it decrease the mortality of cardiovascular patients? So what does it do as in patient inflow to the patient pool, our investment company has going forward? Can dialysis patients live longer and then be dialyzed for a longer period of time? What are the side effects? What is the price of the drug? How many pick it up? The same question you ask us on Biopharma: What is the class uptake? So in essence, I'm saying so many questions out there, we don't feel that we're in a position to make a, already a mathematical model as to how it will pan out. But what I do know is the fundamental trends of all healthcare companies, and this is also true for any kidney disease company, nephrology and dialysis company, is dialysis patients are there, and they're gonna be there, and the disease is growing. So, in essence, a lot of questions, and, there you see my view or our view on the reaction, we all have been seeing. Excellent. That, that's very clear. If I can just quickly sneak in a follow-on to that. I think, Michael, you had said in response to Graham's question that sort of 2024, the starting point should be the margin bands that you've given. At this point in time, do you see any reason why either one of the core businesses would not be sitting within the margin band that you've provided for next year? We did not have the budget meeting yet, so we don't know yet. Sara and I are as curious as you are, but, you know our ambition. I mean, let's face it, Kabi already disclosed to the market what their ambition is. They said, over the course of the next three years, they wanna go to the top end. Now, we may take a ruler or, you know, do we expect them to have a bump and then come up steeper? I don't know. I probably don't guess this will be the case. They shared on every business, actually, how they wanna improve the margin, and this is the starting point also for us. For Helios, it's a stable business, so we gonna rather discuss what are the admission rates. It will be highly dependent on what is the organic growth rate, and what is the case mix. And then we're gonna go into all the depth, what does it mean in terms of volume and price, and then we're gonna come back to you. But, everything we said is valid. Starting point is actual fiscal 2023, and ambition level is out there, and we wanna improve. Great. Thanks so much. ...The next question comes from the line of Hassan Al-Wakeel with Barclays. Please go ahead. Hi, thanks for taking my questions and great to see another strong quarter. I have three, please. So firstly, Michael, when we spoke in June, you said that you were in the process of transacting on divestments and that you had hoped to report back in the next couple of months. I appreciate you've announced Peru, but where are you on the rest, and should we expect much by year-end? And, you know, should we read anything around, you know, the current divestment in terms of LatAm hospitals being non-core? Secondly, just on the back of, you know, the operational strength year to date, could you talk a bit about your confidence about maintaining this momentum into next year and returning to strong EBIT growth for the full year? It's been a long time coming, and I wonder if you could talk to the headwinds and tailwinds as you see them into next year, and whether we should expect the trajectory in margins as linear from here to 2025. And then finally, another strong quarter for nutrition. Can you provide more color on the performance here and share gains, or if it's more that, you know, the buoyant market is driving the strength, you know, based on some of what your enteral peers have reported thus far? And an update on FSMP in China and product registrations would be great. Thank you. Yeah. Look, overall, I think we, both Sara and myself have said, you judge or every investor judge, should judge on what we have been doing up until now, a very short period of time, and we have been delivering, and we want to stay humble, work on our projects, and then come out and report. So I said 12-18 months, that was end of February, in transacting the assets. And as I said, irrespective whether the asset is small or big, it needs preparation, and we don't have an army of people doing carve-outs and M&A and or divestitures. We have people working on several deals. This was the first one. I appreciate that it is small, but it is important. It is important because let me say, and therefore, you said LatAm business, I'm grateful for that one, because we, in essence, didn't have a LatAm business. We had two dispersed countries which had no connection whatsoever with one another. So one was in Peru, where we had the majority stake, which we exited, was actually a nice deal, on the transaction parameters. And then we have a much, you know, more platform-ish kinda asset pack, in in Colombia, where we need to deal with it maybe differently because, as I said, this is an asset pack. It's also highly profitable, and then we'll take it from there. But yes, we are working, day and night. I'm almost, you know, trying to say on other transactions, and we said, expect news soon, that, whatever that means, weeks, months. As I said, the starting point was 12-18 months. Our ambition is to deliver on what we've been saying, so, you can expect more to come. Then, I mean, like Graham also tried it, it feels a little bit like last year when we were on our first call, for Q3 2022 at that time, and everybody wanted to talk about 2024. Same thing here. Let us go through the budget, then we know how everything is panning out. I think we're in a much better position than last year or even in all those years before, because there are clear reference points. There is a framework, and the ambition with the framework is clear. Also, Kabi laid out for each and every business. I'm not sure whether you can take a ruler and do it linear. You need to go business by business, and Kabi, if you remember, the last box on his chart, on Pierluigi's chart, was Biopharma, with arrows going up and down. So that was, you know, the hint that this is a very young business, so this can go either way, but the ambition was clear for all the businesses to improve and go to the upper end of the margin target. For nutrition, actually, we have seen strength all over the place, really broad-based. China, it's, I think, your favorite question. FSMP, we are still getting ready and want to launch actually, I think, two products, two product registration for next year. We're ready for it. Actually, after our call this afternoon, I'm meeting a Chinese delegation. By the same token, Sara alluded to that one in her remarks. Currently, we see softness in China because of what the government is doing there, and that is especially pertaining to all promotional pharmaceuticals, and mostly the promotional pharmaceuticals obviously also have a higher price and therefore contribution margin. Nothing to do with our company. We're working closely with everybody there and are fine, but you see softness, and this is the only precursor I would give for 2024, that we would probably, at least for the first half, also expect some softness on China. Which, by the way, does not mean don't take on- only one particular item that we are not ambitious on the margin-... bands we have. This is the beauty of this margin bands and the reference points, that we do not need to talk about one particular line item and then try to extrapolate for the models. The margin bands are the reference points. Very helpful. Thank you. The next question comes from the line of Victoria Lambert with Berenberg. Please go ahead. Thanks for taking my question. The first one is just on your Actemra biosimilar. When do you think an FDA approval is gonna be achieved? And then when do you think you'll launch the product in the U.S.? And then just on the outlook for your generic pharma business in Q4, organic growth looked a little bit slower in Q3, and one of your competitors also had a weaker Q3 in the U.S. So just wondering what's going on there. It doesn't seem like anyone benefited from the Pfizer tornado. And then lastly, just the outlook for VAMED in Q4, how much better does EBIT look relative to Q3? And is the main driver here, the healthcare services business? Thank you. Yes. Hi, Victoria. Look, on Actemra, also, this one is a broken record in every call. We are not disclosing any launch date for the U.S., out of, you know, confidentiality items we have there. There's no change that we still feel confident that we're gonna be pretty much first to market. And as I said last time, we're working with the FDA. We handed in all papers. Within the process of interacting with the regulatory body, no hiccups, everything has been filed from our side. Now we're waiting for the response. Usually, the response takes roughly six months. On Europe, we're very confident. As I said, we even have the first purchase order, and just launched the whole thing at the beginning of the week. We're the first ones, and, I think, that makes us also confident. And this will be one item, where we need to, you know, get more tangible facts. What does it mean for 2024 when we have our budget meetings and the like? On the U.S., the IV generics, I would say steady. Yes, 1.1%, the U.S. was weaker, because we've said from the outset, we are not going overboard with this Pfizer thing. It was rather that we were focusing on patients and reaching out to the CEO, where can we help? As far as we knew, it was the warehouse, they're up and running. So in August, basically, end of July, August, we saw a big pull. Also, remember, Q2 was actually strong in growth, so probably this was restocking. In September, we saw destocking, and this explains the growth rate in the U.S. So I expect another robust growth rate for Q4, also for the U.S. On VAMED, do you wanna? Sure. Happy, happy to take VAMED. Look, if you look at Q3, or if you look at what we said last quarter, we said that, we expect a turnaround this year. Now, obviously, the EUR 10 million of positive EBIT was a really good positive step in Q3 already. We expect Q4 to be solid. If you look at it, high-end services, and health facility operations, so the services side of the business, there we do see core, and that core is performing, and that core performed in Q3. And you can extrapolate probably that from a Q3 to Q4 perspective. We see that those assets are pointing in the right direction and need to continue to be focused and not get distracted by the overall transformation and also the discontinuation of, parts of the business, which we are also currently executing on. On the project business, you will probably expect that transformation and restructuring takes a bit longer, and this is exactly how we see that it will pan out. So optimistic for another black Q4, where we stand in terms of year-to-date performance. However, clearly, I would say Q4 will not compensate for what we have seen in Q1 and Q2. Great, thank you. The next question comes from the line of Oliver Metzger with Kepler Cheuvreux. Please go ahead. Oh, yeah, thanks so much for taking my questions, three, if Imay. The first one would be on the guidance. If I would take the top end of your upgraded EBIT guidance, I guess it still implies basically kind of flat EBIT in Q4 year on year. Just was trying to understand, is there any kind of base effects that we have to bear in mind for Q4? Secondly, just follow up on China. Obviously, you talked about a softer first half next year and the impact from the anti-corruption campaign. Can you just add a bit more color, what really drives this kind of softness moving to next year? Also, when you talk about softness, can you give us any flavor if softer means slower growth or even decline? Then thirdly, just on Helios, the industry obviously continues to struggle a bit with lack of recovered inpatient volumes, which partly got substituted by outpatient treatments, which obviously have a kind of lower gross contribution. So just, can you provide an update, what you see in your kind of German operations? And considering the EUR 85 million for Helios this year, is there any kind of compensation already visible for next year? Thank you. ... Yeah, Oliver, let me try and then Sara can help. On the Q4, look, we said there is a range of guidance because there's still things floating around. We wanna also stay humble on VAMED. We're all happy that we have a black number there. But as I said earlier this year on other topics, one data point is not a trend. Every action we're taking there is pointing into the right direction, and people are working hard, but they still will have to make it happen. And Q4 will be a lot of work. I mean, by and large, I would be saying this would be like almost copying what we've seen in the first three quarters, quarter by quarter, in terms of what you need to have, as in the growth rate, and then in terms of also, EBIT margins. So everybody is working towards this one. On the risk profile, I've just mentioned one. And then, if we then see more top line growth, this can obviously cater for incremental margin expansion, but taking everything into consideration, this is what we said today. On China, the softness, yeah, I mean, you mentioned it. I mean, what can I say? It is demand driven, and it is behavior driven. We have no crystal ball as to when it will stop. All we see and hear, because we're close to the market, that people are still hesitating, and therefore, the base assumption is that, you know, probably going for into the first half of next year, the volatility or the softness will continue. Then again, the underlying demand obviously is there. So it is, for us, more or less, a timing kind of thing as to when it will pick up and will be going into normality. Helios, I mean, we see numbers actually going up, and we're not absolutely there where we have seen for pre-COVID levels, but we see numbers going up, and we see also an improved case mix. Sara, you wanna? Sure. Happy to, happy to give you a little bit more numbers around that as well. So if you look at it, and echoing what Mike has said, in terms of year-over-year, we actually see year to date, a 4% growth in terms of acute care admission. We see similar in terms of cost weight. And actually, what Mike alluded to is we continue to see slightly higher ratio of complex treatment in our hospitals. Outpatient, probably more stable, and all overall, it's not where we were on a 2019 trajectory, but it's improving year-over-year, what we are seeing today. Obviously, I think this is what we have said from the beginning of the year, we are also very focused on the cost side of things to manage that overall performance, and we are seeing good progress there. I think you also had a second leg to your question, which unfortunately, I think we didn't hear well enough. If you could repeat that, because that slipped. Yeah, of course. Now, basically, the P&L at Helios this year was supported by the EUR 85 million of government help. So is there any, just any kind of color? Is there any kind of additional help on the cards for next year, or is it basically kind of an item you have to compensate for? So if, if you look at it, it comes out of, out of the, regulation and the laws on energy price breaks, and it's the hospital financing law, and that ranges into next year, and we are expecting payments to receive next year. And so we received some this year. We expect to receive some continuing in Q4, but we also expect to receive some next year. Yeah, but maybe let me add, the law has a due date- Sure. ... Has an end date. So I think this may be, Oliver, what you are referring to. Sarah is absolutely right. The timing of the payment will go into next year. There's also a difference between the cash effect and the P&L effect. We can walk you through that one. And obviously, since the law has a termination date, I think April or something like that, until then, you know, folks under the reign of this law, i.e., every hospital is going to receive the payments. And then we expect to, you know, go back to the normal, you know, hospital reimbursement, regulated regime of financing the costs of hospital. That's why I deliberately mentioned this was a pull forward intention of future compensation elements to match with the costs which incurred right now. Okay, perfect. Thanks so much, indeed. The next question comes from the line of James Vane-Tempest with Jefferies International Limited. Please go ahead. Hi, good afternoon. Thanks for taking my questions. Three, if I can, please. When I look at the guidance upgrade, it does seem to be driven by improvements in the corporate line. Certainly 3Q costs were lower than expected. I was just kind of wondering, is this driven by future Fresenius, and what should we expect for the full year for the corporate line items, please? Secondly, on VAMED, you mentioned that the projects business is taking longer to recover. I was just wondering how easy it is to potentially split VAMED. So could one option be to monetize the services business, or- these are run together, you know, the projects business is taking longer to recover. And then my last question is, a number of healthcare services companies have benefited from, I guess, passing through higher, or higher pass-through costs, which, which impact the top line. So I'm not surprised to see the top end of the, the revenue band for Helios, but that potentially comes with margin headwinds. So I'm just kind of curious, in addition to inflation, you know, is that something which you're seeing? And if so, how can that be managed? Thank you. I mean, maybe, maybe, let me take the question and the corporate line. I think on the corporate—I mean, I would focus really on our operating companies if I look for the guidance, and also the improvement we made. It's driven by our operating performance in those, with those two companies. The corporate line, I would expect the run rate to continue. There is not much focus I would revert to on, if I were in your shoes. On the VAMED topic, it is three distinct assets. There is little synergies between the three of them, and they operate in different regions. They operate around the healthcare system. Of course, that is what they have in common. But you can also see in terms of the transformation work we are currently undergoing and the restructuring, they are all pointing into also different ways in terms of where their future focus is on. And your last question was on, Inflationary effects on Helios. Inflationary effects on Helios. Coming back to that, of course, we are seeing and have seen inflationary effects on the cost base of Helios throughout, right? And in particular, starting in the second half of last year already. Now, in terms of top line, we have been successful to see price increases. I think if you look at Spain, it's a very different, reimbursement and stakeholder system compared to Germany. And in Spain, yes, it's a good mix of volume growth, and also some price, adjustments and, increases we are seeing when we look at the top line in Spain, and that is compensating part of what we are seeing in terms of cost inflationary increases. We have renegotiated around 80% of all of our workforce contracts this year, and obviously, we feel and see that inflation. I would say so far, we have managed it quite well and, we can be quite comfortable with the achievements we have made there. In Germany, similar. Yeah. Let me maybe add to that one, in a, in a broader context. We introduced the Fresenius financial framework with the margin bands in order to establish a performance culture, in order also the structural productivity, i.e., that means if something is going against your margin, there are levers to be taken. Obviously, first of all, you can grow by volume, and then you can go grow by price. On the hospital business, you can, try to manage to increase your mix, your case mix, and then you have an entire cost base, which can be attacked, and there are levers to do this. And, I, I think our businesses are getting into that flow, and this is the discussion we have. So yes, there is also inflation, inflationary pressures going forward. This year, they have been extraordinary. That's why the, the compensation. For the Spanish asset, for example, when also negotiating the new contracts, the inflation also plays a crucial role. So what I'm trying to say, there are enough levers for management to compensate. If there is something extraordinary, then obviously we have to talk. Thank you. Just a quick clarification on my first question. I know you're sort of suggesting to, to focus on the operating companies, but if I can come back to the, the corporate line. If you're saying the run rate, are you saying, you know, Q3 is what we should expect for the Q4 number, or nine months we gross up for the full year? If you don't want to give us a specific number, I guess you have done in the past, how should we think about that for the full year? Let me follow up exactly with that number. I think what you can take for the full year is something similar to last year, maybe a notch higher, depending how it really pans out, but I would take with, I would go with that. That's great. Thank you. The next question comes from the line of Sezgi Öztürk with HSBC. Please go ahead. Hi. Thanks for taking my questions. I will have tea, please. In terms of the LatAm business, you've obviously announced a Peru hospital sale with no financial indication so far. Looking at the weight that LatAm had in your ex-FMC figures and the growth rate I see at close to 30% for the nine months. So the question that follows is: How much is the EBITDA approximately that goes with the sale? And together with the Colombian business, how much of the EBITDA these two businesses would represent? You also had some write-downs in the recent years from the LatAm businesses. So were these businesses, some of the businesses that were written down in book value, such that we might see financial gains from the transactions going forward? My next question is related to the interest in divestments we've been seeing in markets, private equity companies having a hard time coming to market or exiting deals. So since you've started this transformation and said 5+ assets would be for sale, has the interest for these assets changed, and the outlook for you changed? How are you seeing interest in these assets going currently? And the last one is related to the regulation in Germany, the dividend aspects of this, where it was discussed a lot, but I believe there's also a bonus perspective to it. Does this regulation prevent you from paying the management incentives? If it does, what would be your stance towards this? Like, can you make it up somehow and keep management motivated? Yeah. I'll try to start, not quite sure whether if everything would happen in the past in terms of write-offs in LatAm. I'm not aware of this one. First thing is, it is interesting. Now it's 5+ assets. I said a handful of assets in on February 22. The second thing on LatAm, it is important to understand what I mentioned is not LatAm. It is two separate countries, and also the nature of the makeup is different. As I said, in Colombia, it's more, it's a whole array of hospitals, and it's more kind of like a platform-ish kind of business. And therefore, it is different to what we had in Peru, where it was a very attractive hospital, but we had a majority stake. So we exited that one. That is correct. And how... What can I say? The deal parameters are actually very nice. We roughly, I mean, we can say we have a double-digit proceeds coming into the company, and we created value over the course of our ownership. Again, Colombia is something different. Then on the dividends, yes, you're correct. With the fine print, whatever you decide, the dividend is also tied to the bonus, but this is nothing we have to decide. This is something the supervisory board usually decides how to deal with our bonus. But what I'm trying to say is we are making a decision with the key parameter in mind that we honor—are going to decide what is the best in the interest of the shareholder. Any write-offs? I am not aware of the write-offs. No. If not, then, if you could call up Markus and the team, and then they can come back to you. Happy to. And interest in divestments, any change in appetite for the assets? I mean, if you have attractive assets, you will have interest, but it always depends on the counterparty. You know, the environment is the environment, you know, for probably for financial sponsors, it's a little heavier with higher interest rates. If somebody has a strategic interest, that depends. I mean, this is why it also takes the time it takes. Every deal is different. Every deal needs to be prepared with documents, vendor due diligence, and so on and so forth. And then depending on what the asset is, we need to also prepare everything, talk to counterparties. If synergies are involved, obviously there is deep dive discussions, and that's why I said 12-18 months. But I also want to put out the notion we are progressing with other deals in the pipeline. Thanks very much. Ladies and gentlemen, that was the last question. I would now like to turn the conference back over to Markus Georgi for any closing remarks. Thanks, Andrea. Many thanks for your attention and joining today's conference call. If there are any further questions or open topics you would like to discuss, please contact the IR team. And with that, thank you and goodbye. We want to thank Fred Zeniuss and all the participants for taking part on this conference call. Goodbye.